Folic acid and B vitamins improve hyperhomocysteinemia-induced cardiovascular risk profile in renal transplant recipients [5]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 5, 2007, Pages 1072-1076

  Manrique, J ^a   Errasti, P ^a   Orbe, J ^b   Paramo J A ^b   Rodríguez, José A ^b,c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CYANOCOBALAMIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRIDOXINE; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN B COMPLEX;

EID: 34247863944     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02506.x     Document Type: Letter

References (24)

1. Sarnak M. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 2003; 108: 2154.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002; 288: 2015-22.
3. Bostom A, Shemin D, Lapane K, Miller J, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson P. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 1995; 114: 93-103.
4. Friedman A, Bostom A, Selhub J, Levey A, Rosenberg I. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181-9.
5. Bayes B. "New" cardiovascular risk factors in patients with chronic kidney disease: Role of folic acid treatment. Kidney Int 2005; 93 (Suppl.) s39.
6. Manrique J, Errasti P, Lavilla J, Rossich E, Hernandez A, Pujante D, Garcia-Fernandez N, Purroy A. Treatment of hyperhomocysteinemia after renal transplantation. Transplant Proc 2003; 35: 1742-4.
7. Eikelboom J, Hankey G. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 2001; 10: 377-83.
8. Mayer O, Filipovsky J, Hromadka M, Svobodova V, Racek J, Stehlik P, Trefil L, Zarybnicka M. Treatment of hyperhomocysteinemia with folic acid: Effects on homocysteine levels, coagulation status, and oxidative stress markers. J Cardiovasc Pharmacol 2002; 39: 851-7.
9. Corretti M, Anderson T, Benjamin E, Celermajer D, Charbonneau F, Creager M, Deanfield J, Drexler H. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
10. Sobki S, Khan S, Al Mofawaz T, Saadeddin S, Al Suliman M, Al Khader A. Homocysteine in renal transplant recipients: Association with transplant duration and renal function. Ren Fail 2004; 26: 265-71.
11. Perna A, Ingrosso D, Lombardi C, Cesare C, Acantora F, Satta E, De Santo N. Homocysteine in uremia. Am J Kidney Dis 2003; 41: S123-6.
12. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: A critical review of the evidence. JAMA 2003; 290: 932-40.
13. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004; 103: 1728-34.
14. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodriguez JA, Diez J, Libby P, Paramo JA. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47: 1369-78.
15. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55.
16. Woo K, Chook P, Lolin Y, Sanderson J, Metreweli C, Celermajer D. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34: 2002-6.
17. Marcucci R. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 2003; 75: 1551-5.
18. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, Goodfellow J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002; 105: 22-6.
19. van Guldener C, Janssen M, Lambert J, ter Wee P, Jakobs C, Donker A, Stehouwer C. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106-12.
20. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47: 1108-16.
21. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM. Effect of aggressive risk factor modification on cardiac events and myocardial ischemia in patients with chronic kidney disease. Heart 2006; 92: 1402-8.
22. Toole J, Malinow M, Chambless L, Spence J, Pettigrew L, Howard V, Sides E, Wang C, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
23. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest Jr J. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
24. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.